Global Retirement Partners LLC Takes $472,000 Position in DexCom, Inc. $DXCM

Global Retirement Partners LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,407 shares of the medical device company’s stock, valued at approximately $472,000.

Several other large investors also recently added to or reduced their stakes in the stock. Andra AP fonden purchased a new position in shares of DexCom during the second quarter worth approximately $26,000. Zions Bancorporation National Association UT bought a new position in DexCom in the first quarter worth approximately $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom during the 1st quarter worth $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom during the 2nd quarter valued at $45,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of DexCom in the 2nd quarter worth $70,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 1.5%

Shares of DexCom stock opened at $63.46 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market cap of $24.75 billion, a P/E ratio of 44.07, a PEG ratio of 1.43 and a beta of 1.40. The firm’s 50 day moving average price is $64.31 and its 200-day moving average price is $75.83. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the firm earned $0.45 earnings per share. DexCom’s revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other news, Director Kyle Malady sold 667 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,999 shares of company stock worth $619,391 over the last quarter. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on DXCM shares. Citigroup cut their price target on DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Wells Fargo & Company set a $93.00 target price on shares of DexCom and gave the company an “overweight” rating in a research report on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and issued a $82.00 price target (down previously from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Royal Bank Of Canada dropped their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Finally, Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, October 24th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $86.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.